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and analyzed for the treatment phase. In addition, an interim
analysis of the subsequent observation period was conducted.
Patients were treated before the DRG-system was introduced in
Germany. Therefore, length of each hospitalisation was used as
proxy for case-complexity and as criterion for assignment to one
of 3 DRGxs relevant for NHL-patients. Several sensitivity analy-
ses were performed to address different DRG-grouping criteria
and discounting scenarios. RESULTS: Mean cost per treatment
cycle was €2700 for R-MCP and €1900 for MCP (p < 0.0001).
Mean observation periods after end of initial treatment were
21.2 months for R-MCP and 17.6 months for MCP (p = 0.02).
Hospitalisations for adverse events (−32%), new chemotherapies
(−33%), treatment of progressive disease (−55%) and other
reasons (−39%) were reduced in the R-MCP arm. This resulted
in mean, undiscounted cost per patient in the observation period
of €4600 for R-MCP and €7700 for MCP (p = 0.02). To adjust
for the difference in length of the observation period overall
monthly costs were calculated and amounted to €1230 for R-
MCP and €1290 for MCP (p = 0.67). Sensitivity analyses did not
result in major changes. Clinically, R-MCP resulted in an objec-
tive response rate of 85.6% vs. 65.5% with MCP. After two
years event free survival for R-MCP was 69% vs. 44% for MCP
alone (p < 0.001). CONCLUSION: Initially higher treatment
costs of R-MCP were compensated by savings due to better efﬁ-
cacy. Combined with the clinical superiority of R-MCP, this
regime is likely to prevail as the dominant treatment strategy
compared to MCP alone at the ﬁnal analysis.
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OBJECTIVES: In breast cancer, primary prophylaxis with peg-
ﬁlgrastim has been shown to improve health outcomes but its
cost-effectiveness has not been evaluated in the French setting.
Filgrastim is often used for less than the recommended 11 days
(e.g., 5–6 days), which has been associated with sub-optimal out-
comes. This study compared the cost-effectiveness of pegﬁlgras-
tim versus 11- and 6-day ﬁlgrastim primary prophylaxis in
women with stage I–III breast cancer receiving chemotherapy
with moderate to high FN risk in France. METHODS: A deci-
sion-analytic model was constructed from a health care payer’s
perspective. Costs included drugs, drug administration, FN-
related hospitalizations and subsequent costs, and were based on
ex-factory price listing and DRG Tariff. Effectiveness was mea-
sured as FN avoided and life-year-gained (LYG). FN risk (varied
by days of ﬁlgrastim), FN case-fatality, relative dose intensity
(RDI), and the impact of RDI on survival were based on a com-
prehensive literature review and expert panel validation. Breast
cancer mortality and all-cause mortality were taken from ofﬁcial
statistics. Model robustness was tested using sensitivity analyses.
RESULTS: Compared with 11 days of ﬁlgrastim, pegﬁlgrastim
saved costs and was more effective. Compared with 6-day 
ﬁlgrastim, pegﬁlgrastim avoided 10.5 absolute percentage point
of FN (17.5% vs. 7%). The incremental cost-effectiveness 
ratio (ICER) was €10,295 per FN avoided. The average life
expectancy was 16.27 years with pegﬁlgrastim and 16.16 years
with ﬁlgrastim, yielding an ICER of €9652/LYG. Age of diag-
nosis and cancer stage had minimal impact on the results. Key
inﬂuencing factors included relative costs of drugs and relative
risk of FN. CONCLUSIONS: Use of pegﬁlgrastim in France may
dominate 11-day use of ﬁlgrastim and is cost-effective compared
to 6-day use of ﬁlgrastim. The cost-effectiveness ratio is signiﬁ-
cantly below the commonly used threshold for cost-effectiveness
ratios in Europe.
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OBJECTIVES: An original decision model has shown that
methyl-aminolevulinate (MAL) is a cost-effective intervention in
AK and better value for money than excision in BCC. The objec-
tive of this observational study was to conﬁrm these results in
real life in Belgium from a health-care-payers perspective.
METHODS: The study was a prospective, multi-centre obser-
vational study in which patients meeting criteria for MAL-
treatment were followed for 6 months after ﬁrst application of
methyl-aminolevulinate. Clinical response (CR) and cosmetic
outcome (CO) were evaluated at the last available visit during
the follow-up period. Socio-demographic data, treatment related
data and safety data were collected. Inclusion period was
October 2004–October 2005. RESULTS: 247 patients were eval-
uated (mean age: 69 years; 53% males). 47% of patients had AK
with an average of 7.1 ± 0.4 lesions (32% new lesions); BCC-
patients had an average of 1.7 ± 0.2 lesions (89% new lesions).
As the majority of patients had multiple lesions, on average
0.797 tube of MAL was used per patient. AK patients had a
mean of 3.9 dermatologist visits related to diagnosis, treatment
and follow-up (BCC: 4.2 visits). In 83% of AK and in 84% of
BCC patients, all lesions showed a complete CR. Good to excel-
lent CO was found in 95% and 93% of AK and BCC patients
respectively. Total cost of care (MAL-treatment plus follow-up)
was €383 in AK and €298 in BCC-patients, with a higher effec-
tiveness compared to the model. The model showed €255 for AK
and €303 for BCC. Higher costs in AK were due to a higher
mean number of lesions per patient compared to the model pop-
ulation (4.1 lesions per patient). CONCLUSIONS: This obser-
vational study conﬁrms the cost-effectiveness shown in the
original model for methyl-aminolevulinate in AK and BCC and
shows that real-life data can be used to reﬁne original decision
models.
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OBJECTIVE: To compare the cost-effectiveness of therapy with
erlotinib (ERL), docetaxel (DOC), pemetrexed (PEM) or best
supportive care (BSC) in patients with advanced non-small cell
lung cancer (NSCLC) in Spain. METHODS: A Markov model
with 3 health states (progression free, disease progression and
dead) was developed. Time horizon: 2 years (monthly cycles).
Survival and time to progression were obtained from 3 clinical
trials. Utilities were obtained from a study performed in UK in
154 patients. National Health System (NHS) perspective (direct
health costs) was applied. Resources used were estimated from
